Partnering
Pharma Partnerships
Enabling better decisions across discovery and clinical development
Wobble Genomics partners with pharmaceutical and diagnostics companies to integrate full-length RNA sequencing and AI-driven analytics into drug development.
By combining ATLUS Targeting with TAMA™ Analytics, we enable deeper biological insight to improve patient selection, target discovery, and clinical outcomes.
Work With Us
We offer flexible collaboration models tailored to each partner’s needs, supporting programmes from early discovery through to clinical implementation.
Patient Stratification and Trial Design
Precision cohort selection for clinical success
ATLUS Targeting captures full-length RNA transcripts with high sensitivity, enabling accurate identification of clinically relevant genes, isoforms, and fusion events directly from patient samples.
TAMA™ Analytics translates this data into actionable insights, identifying biomarkers and transcriptomic signatures associated with treatment response and resistance.
What It Enables
Refined Patient Stratification
Precise identification of patient subgroups based on transcript-level biology.
Optimised Trial Design
Data-driven cohort selection to improve trial outcomes and reduce risk.
Longitudinal Monitoring
Tracking of treatment response and emerging resistance over time.
Why Partner
Improve patient selection and increase the probability of clinical success.
Wobble Genomics enables more efficient trials, reduced risk, and faster progression through development.
Patient Stratification and Trial Design
Precision cohort selection for clinical success
ATLUS Targeting captures full-length RNA transcripts with high sensitivity, enabling accurate identification of clinically relevant genes, isoforms, and fusion events directly from patient samples.
TAMA™ Analytics translates this data into actionable insights, identifying biomarkers and transcriptomic signatures associated with treatment response and resistance.
What It Enables
Refined Patient Stratification
Precise identification of patient subgroups based on transcript-level biology.
Optimised Trial Design
Data-driven cohort selection to improve trial outcomes and reduce risk.
Longitudinal Monitoring
Tracking of treatment response and emerging resistance over time.
Why Partner
Improve patient selection and increase the probability of clinical success.
Wobble Genomics enables more efficient trials, reduced risk, and faster progression through development.
Target Discovery
Identifying novel, high-value therapeutic targets
ATLUS Targeting enables high resolution analysis of full-lenth RNA transcripts, including isoforms, splice variants, and fusion events, whilst preserving transcriptome-wide context.
TAMA™ Analytics transforms this data into prioritised insights, identifying novel targets and functionally relevant transcript variants linked to disease mechanisms.
What It Enables
Novel Target Identification
Discovery of previously inaccessible targets, including rare isoforms and fusion-driven drivers.
Biological Context
Understanding how targets function within broader regulatory and signalling networks.
Target Validation
Linking transcript structure to function, expression, and clinical relevance.
Why Partner
Discover and prioritise higher-value targets with greater confidence.
Wobble Genomics enables partners to identify more precise, biologically relevant targets – improving downstream success in drug development.
Target Discovery
Identifying novel, high-value therapeutic targets
ATLUS Targeting enables high resolution analysis of full-lenth RNA transcripts, including isoforms, splice variants, and fusion events, whilst preserving transcriptome-wide context.
TAMA™ Analytics transforms this data into prioritised insights, identifying novel targets and functionally relevant transcript variants linked to disease mechanisms.
What It Enables
Novel Target Identification
Discovery of previously inaccessible targets, including rare isoforms and fusion-driven drivers.
Biological Context
Understanding how targets function within broader regulatory and signalling networks.
Target Validation
Linking transcript structure to function, expression, and clinical relevance.
Why Partner
Discover and prioritise higher-value targets with greater confidence.
Wobble Genomics enables partners to identify more precise, biologically relevant targets – improving downstream success in drug development.
Companion Diagnostics (CDx)
Enabling precision therapies through transcript-level insight
Wobble Genomics partners with pharmaceutical and diagnostics companies to develop next-generation companion diagnostics for targeted therapies, including antibody-drug conjugates (ADCs).
ATLUS Targeting captures full-length RNA transcripts with high sensitivity, enabling accurate detection of gene expression, isoforms, and fusion events directly from patient samples.
TAMA™ Analytics translates this data into clinically actionable insights, identifying and prioritising biomarkers associated with treatment response, resistance, and patient outcomes.
What It Enables
Biomarker Discovery and Validation
Identification of clinically relevant biomarkers to guide patient selection.
Precision Patient Stratification
Development of robust diagnostic signatures to match therapies to the right patients.
End-to-End CDx Development
Support from early discovery through clinical validation and trial integration.
Why Partner
Develop more precise and clinically relevant diagnostics to improve treatment outcomes.
Wobble Genomics enables partners to build robust companion diagnostics that increase therapeutic efficacy, reduce risk, and support successful clinical development.
Companion Diagnostics (CDx)
Enabling precision therapies through transcript-level insight
Wobble Genomics partners with pharmaceutical and diagnostics companies to develop next-generation companion diagnostics for targeted therapies, including antibody-drug conjugates (ADCs).
ATLUS Targeting captures full-length RNA transcripts with high sensitivity, enabling accurate detection of gene expression, isoforms, and fusion events directly from patient samples.
TAMA™ Analytics translates this data into clinically actionable insights, identifying and prioritising biomarkers associated with treatment response, resistance, and patient outcomes.
What It Enables
Biomarker Discovery and Validation
Identification of clinically relevant biomarkers to guide patient selection.
Precision Patient Stratification
Development of robust diagnostic signatures to match therapies to the right patients.
End-to-End CDx Development
Support from early discovery through clinical validation and trial integration.
Why Partner
Develop more precise and clinically relevant diagnostics to improve treatment outcomes.
Wobble Genomics enables partners to build robust companion diagnostics that increase therapeutic efficacy, reduce risk, and support successful clinical development.
